INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Option exerciseVerified data

van Houte Hans reported NRIX

Chief Financial Officer · Nurix Therapeutics, Inc. · Common Stock

Side
M
Value
—
Shares
3,750
Price
—
Executed
Jan 30, 2026
Disclosed
Jan 30, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jan 30 executedJan 30, 2026 disclosed

NRIX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 8.8% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NRIX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$24K
    1,469 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    0
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    5,786 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$245K
    9,527 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$29K
    1,075 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    23
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$158K
    6,113 sh
    		Nov 3, 2026Nov 4, 2026
    traded Nov 3, 2026
    		+1dSEC FORM 4

    Evidence

    18
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$51K
    3,300 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    3
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$50K
    5,786 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    HG
    Hansen GwennChief Scientific Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,573 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    17
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,750 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    14
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,750 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    4
    HG
    Hansen GwennChief Scientific Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,750 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    13
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    2,859 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    6
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,573 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    0
    HG
    Hansen GwennChief Scientific Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    2,859 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,750 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,573 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    0
    HG
    Hansen GwennChief Scientific Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$2,701
    1,452 sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    10
    RC
    Ring ChristineChief Legal Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,573 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    0
    HG
    Hansen GwennChief Scientific Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,452 sh
    		Nov 2, 2026Nov 2, 2026
    traded Nov 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    VH
    van Houte HansChief Financial Officer
    NRIXNurix Therapeutics, Inc.
    Option exercise
    		M—
    3,573 sh
    		Oct 30, 2026Nov 2, 2026
    traded Oct 30, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001817217-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 30, 2026
    Published
    Jan 30, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    van Houte Hans
    Role
    Chief Financial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Nurix Therapeutics, Inc.
    Ticker
    NRIX
    Shares
    3,750
    Price per share
    $0
    Execution date (reported)
    Jan 30, 2026
    Owned after transaction
    46.2K shares
    Days from execution to publication
    0

    What this establishes

    van Houte Hans filed this Form 4 reporting a option exercise of NRIX on Jan 30, 2026. It became public on Jan 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    van Houte Hanscik:0001817217
    Issuer
    Nurix Therapeutics, Inc.cik:0001549595

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.